Provided by Tiger Fintech (Singapore) Pte. Ltd.

Altimmune, Inc.

3.57
-0.0600-1.65%
Volume:1.75M
Turnover:6.32M
Market Cap:315.08M
PE:-3.04
High:3.68
Open:3.63
Low:3.55
Close:3.63
52wk High:11.16
52wk Low:2.90
Shares:88.26M
Float Shares:80.42M
Volume Ratio:0.93
T/O Rate:2.18%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.1725
EPS(LYR):-1.3388
ROE:-55.91%
ROA:-32.43%
PB:1.95
PE(LYR):-2.67

Loading ...

BRIEF-Altimmune Appoints Linda M. Richardson As Chief Commercial Officer

Reuters
·
Sep 15

Press Release: Altimmune Appoints Accomplished Commercial Executive Linda M. Richardson as Chief Commercial Officer

Dow Jones
·
Sep 15

Bitcoin above first major resistance level with ALT coins rallying

Kitco
·
Sep 11

Altimmune Inc. Faces Class Action Lawsuit Over Alleged Securities Fraud by Investors

Reuters
·
Aug 28

Altimmune Announces FDA Fast Track Designation for Pemvidutide in Alcohol Use Disorder (AUD)

THOMSON REUTERS
·
Aug 19

Altimmune Inc. Faces Class Action Lawsuit Following Disappointing Phase 2b Trial Results and Stock Plunge

Reuters
·
Aug 19

These Analysts Slash Their Forecasts On Altimmune Following Q2 Results

Benzinga
·
Aug 14

Altimmune Price Target Maintained With a $12.00/Share by HC Wainwright & Co.

Dow Jones
·
Aug 14

UBS Adjusts Price Target on Altimmune to $24 From $26, Maintains Buy Rating

MT Newswires Live
·
Aug 13

Altimmune Inc : UBS Cuts Target Price to $24 From $26

THOMSON REUTERS
·
Aug 13

Altimmune Q2 FY2025 Earnings Call Transcript

Benzinga
·
Aug 12

Altimmune Inc reports results for the quarter ended June 30 - Earnings Summary

Reuters
·
Aug 12

Altimmune Q2 EPS $(0.27) Beats $(0.32) Estimate, Sales $5.000K Beat $560.000 Estimate

Benzinga
·
Aug 12

Altimmune Q2 Revenue USD 5 Thousand VS. Ibes Estimate USD 1.2 Thousand

THOMSON REUTERS
·
Aug 12

Altimmune Q2 Basic EPS USD -0.27

THOMSON REUTERS
·
Aug 12

Altimmune Names Jerry Durso Chair

MT Newswires Live
·
Aug 11

Altimmune Board of Directors Appoints Jerry Durso as Chairman

THOMSON REUTERS
·
Aug 11

Altimmune Inc expected to post a loss of 32 cents a share - Earnings Preview

Reuters
·
Aug 08

Immunocore reports second quarter financial results and provides a business update

GlobeNewswire
·
Aug 07

Assembly Biosciences Reports Interim Phase 1a Data from Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus

GlobeNewswire
·
Aug 07